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Abstract 
Eosinophilic esophagitis (EoE) is a leading cause of dysphagia and food impaction in children and adults. The diagno-
sis relies on histological examination of esophageal mucosal biopsies and requires the presence of > 15 eosinophils 
per high-powered field. Potential pitfalls include the impact of biopsy sectioning as well as regional variations of 
eosinophil density. We performed genome-wide DNA methylation analyses on 30 esophageal biopsies obtained 
from children diagnosed with EoE (n = 7) and matched controls (n = 13) at the time of diagnosis as well as following 
first-line treatment. Analyses revealed striking disease-associated differences in mucosal DNA methylation profiles in 
children diagnosed with EoE, highlighting the potential for these epigenetic signatures to be developed into clinically 
applicable biomarkers.
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Introduction
Eosinophilic esophagitis (EoE) is a chronic, allergic/
immune-mediated inflammatory disease and the lead-
ing cause of dysphagia and food impaction in children 
as well as adults [1]. The condition and its symptoms 
have a major impact on patient health and quality of life, 
resulting in a substantial healthcare burden as the disease 
requires complex diagnostic and treatment approaches 
[2]. Diagnosis relies on the presence of symptoms sug-
gestive of esophageal dysfunction and eosinophilic 
infiltration of the esophageal mucosa (i.e., the presence 
of ≥ 15 eosinophils per high-powered field, eos/hpf) [3]. 
Potential diagnostic pitfalls include the impact of biopsy 
sectioning, as well as regional variations of eosinophil 
density [4]. Furthermore, a reduction in eosinophils 
following treatment does not always coincide with 
improved clinical symptoms, suggesting that other mech-
anisms also contribute to disease pathogenesis [5]. Can-
didate gene and genome-wide association studies have 
identified several disease-associated susceptibility genes 
for EoE; however, given the rapid increase in incidence, 
as well as a wide variation of clinical phenotype and out-
come, genetic variation is unlikely to be the sole contrib-
uting factor [6]. Increasingly, environmental factors and 
their potential impact on the human epigenome of dis-
ease relevant cell types are being considered [6]. A poten-
tially promising epigenetic marker is DNA methylation. 
Operating in a highly cell type specific manner, this stable 
epigenetic marker has been used as a proxy to determine 
cell composition in mixed cell tissue samples, as well as 
in the development of clinical biomarkers [7–9]. Indeed, 
a recent study by Jensen and colleagues has highlighted 
distinct differences in the DNA methylation profile of 
esophageal biopsies in EoE patients according to treat-
ment response [5]. Nevertheless, the potential role of 
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epigenetic mechanisms in EoE disease pathogenesis and/
or the value of DNA methylation signatures as clinical 
biomarkers remains poorly understood.
Here, we set out to perform genome-wide DNA meth-
ylation analyses on esophageal biopsies obtained from 
children with EoE and matched controls, with an aim to 
identify disease specific epigenetic signatures that could 
be of potential clinical value.
Methods
Patients
A total of 20 children aged between 4 and 16 years were 
prospectively recruited following informed consent. Ethi-
cal approval for this study was obtained from the Institu-
tional Review Board of the University of Naples “Federico 
II” with the registration number 247/20. Diagnosis of 
Eosinophilic Esophagitis (EoE) was made according to 
current UEG guidelines [10]. Further details can be found 
in the Additional file 3: Supplementary Methods. In total, 
we obtained 30 esophageal biopsies from patients diag-
nosed with EoE (n = 7) and matched non-EoE/healthy 
controls (n = 13). Patients were sampled at the point 
of diagnosis (i.e., treatment naïve), and a further biopsy 
sample was obtained following completion of first-line 
treatment (8 weeks of treatment). All patients were meas-
ured for number of eosinophils per high-powered field 
(eos/hpf) at diagnosis prior to treatment (T0) and again 
on follow-up after treatment (T1).
Sample processing and DNA methylation profiling
DNA was extracted from mucosal biopsies using the All-
Prep MiniKit (Qiagen), according to the manufacturer’s 
instructions and bisulfite—converted using Zymo DNA 
methylation Gold kit (Zymo Research). Genome-wide 
DNA methylation was profiled using the Illumina EPIC 
BeadChip platform (Illumina, Cambridge, UK).
Data pre‑processing and quality control
A detailed description and references for all analyses 
can be found in the Additional file 3: Methods. In brief, 
raw intensity data were processed to extract beta values 
from IDAT files. Data were then normalized using inter-
nal control probes to correct for between-array technical 
variation, filtered to remove poor quality or potentially 
confounding probes and checked for batch effects. No 
batch effects were observed. Principal component (PC) 
analysis was performed on the filtered dataset, identify-
ing one outlier which was removed from all downstream 
analyses. Correlation with clinical phenotype and array 
batch was measured using Kendall’s test statistic for con-
tinuous variables and ANOVA for categorical variables. 
Biological duplicate samples were taken from middle 
esophagus for 5 patients (2 controls, 1 patient at diag-
nosis and 2 patients after treatment), and each duplicate 
pair checked for correlation  (R2 = 0.79 – 0.85, Additional 
file 1: Supplementary Fig. 1).
Differential methylation
Duplicate samples were removed, and M-values calcu-
lated from the filtered beta values. Differential meth-
ylation analyses were then performed using the limma 
v3.42.2 [11] and DMRcate v2.0.7 [12] packages to detect 
differentially methylated positions (DMPs) and regions 
(DMRs), respectively, using a linear model with age and 
gender as covariates. To be considered as significantly 
differentially methylated, CpGs needed to have a False 
Discovery Rate (FDR) p-value < 0.01 and an absolute 
methylation difference (Δβ) > 0.05.
Epigenetic clock
Normalised, filtered beta values were used to estimate 
epigenetic age using the Horvath online DNA Methyla-
tion Age Calculator [13] according to the recommended 
guidelines and resulting values compared to biological 
age.
(See figure on next page.)
Fig. 1 a Principal components plot (PC1, PC2) depicting patient diagnosis with number of eosinophils per high-powered field (eos/hpf ) in controls 
(n = 13), and in EoE patients at diagnosis (EoE T0, n = 6) and after treatment (EoE T1, n = 5) after quality control. b Observed variance within all at 
diagnosis (T0) patient (n = 6) and non-EoE control samples (n = 13) in the first 10 principal components (top panel) against a heatmap showing 
the correlation between each principal component and phenotype, measured using Kendall’s test statistic for continuous variables and ANOVA for 
categorical variables (bottom panel). c Clustering of EoE patients at diagnosis (T0) and non-EoE controls (total n = 19) in all CpGs passing quality 
control using Pearson’s correlation with average clustering. The two principal clusters determined by hierarchical clustering are indicated in green 
and brown. d Summary of the significant differential methylation analysis results. To be considered as significantly differentially methylated, CpGs 
needed to have a False Discovery Rate (FDR) p-value < 0.01 and an absolute methylation difference (Δβ) ≥ 0.05. e Heatmap of all samples after 
quality control, excluding outliers but including biological duplicates (n = 29) subset for the top 25 CpGs significantly differentially methylated 
between EoE patients at diagnosis (T0) and non-EoE controls (FDR p < 0.01 and Δβ ≥|0.05|) using Pearson’s correlation with average clustering. 
DMP = Differentially methylated position, DMR = Differentially methylated region. EoE T0 = EoE patients at diagnosis, EoE T1 = EoE patients after first 
treatment






Page 4 of 5Strisciuglio et al. Clin Epigenet           (2021) 13:81 
Results
Principal component analyses (PCA) of genome-wide 
DNA methylation profiles revealed a distinct separation 
of esophageal biopsies obtained from children newly 
diagnosed (i.e., treatment naïve) with EoE (n = 7) from 
healthy controls (n = 13, Fig.  1a). Interestingly, although 
DNA methylation signatures of biopsies obtained from 
EoE patients at a later stage of the disease (following 
first-line treatment) mostly displayed global changes 
(indicated by lines between samples Fig.  1a), the clear 
separation from normal controls remained. Next, we 
performed variance decomposition analyses in order 
to identify the main phenotypic factors contributing to 
observed variation in mucosal DNA methylation signa-
tures. As shown in Fig. 1b, variation in DNA methylation 
profiles was significantly associated with diagnosis, num-
ber of eosinophils, as well as with age. Indeed, perform-
ing unsupervised clustering analysis further confirmed 
the presence of disease-associated DNA methylation 
signatures in patients diagnosed with EoE compared 
to healthy controls as clear clusters emerge that sepa-
rate EoE patient from the majority of control samples 
(Fig. 1c).
In order to explore specific DNA methylation differ-
ences between patients with EoE and non-EoE controls 
that might form the basis for a potential diagnostic signa-
ture, we performed differential DNA methylation analy-
ses. Given relatively low sample numbers, resulting in 
an inability to detect small methylation differences with 
confidence, we used a stringent threshold of significance, 
aiming to detect CpGs displaying a large effect size (false 
discovery rate, FDR, corrected p-value < 0.01 and an 
absolute methylation difference, Δβ, between groups of 
0.05). This analysis yielded a total of n = 2,481 significant 
differentially methylated positions (DMPs) grouped into 
428 differentially methylated regions (DMRs) between 
EoE patients and non-EoE controls at diagnosis and 
n = 4,379 DMPs (626 DMRs) between controls and EoE 
at follow-up (i.e., Time point T1). An overlap of n = 665 
DMPs (204 DMRs) was identified between both compari-
sons, while analysis of EoE patients at diagnosis against 
EoE patients at T1 did not yield any significant DMPs 
even without filtering for results with Δβ ≥ 0.5 (Fig. 1d). 
Given that sample numbers for this final comparison are 
particularly low, it is possible that the lack of significant 
DMPs results from the  increase in type II error expected 
in an experiment of this size and replication in larger 
datasets would be desirable, albeit beyond the scope of 
this study.
Based on previous reports of accelerated epigenetic 
age in the esophageal mucosa of EoE patients [5], we 
applied the Horvath online DNA Methylation Age Cal-
culator [13] to estimate epigenetic age. Although these 
analyses confirmed a strong correlation with chrono-
logical age  (R2 ≥ 0.8, p < 0.002, Additional file  2: Sup-
plementary  Fig.  2A & B), a comparison of EoE patients 
with non-EoE controls did not support the previously 
reported significantly disease-associated acceleration in 
epigenetic aging (p > 0.05 in our data) [5].
Finally, in order to evaluate the potential value of 
DNA methylation as a diagnostic biomarker in EoE, 
we selected the top 25 most significant DMPs resulting 
from the comparison between EoE patients at diagno-
sis and healthy controls (Additional file  4: Supplemen-
tary Table 2) to cluster all available samples. As shown in 
Fig.  1E, unsupervised clustering separated EoE samples 
from non-EoE controls with an accuracy of 0.90 (true 
positive rate = 0.79, false positive rate = 0). Correlation 
between the methylation signature and eosinophil count 
was also confirmed (p < 0.005).
Discussion
DNA methylation has been shown in many studies to be 
a highly stable, and relatively easy to profile epigenetic 
mark, making it an ideal candidate for the development 
of clinically relevant biomarkers [8, 9]. Furthermore, 
DNA methylation signatures are highly cell type spe-
cific and have been used to deconvolute the composi-
tion of mixed cell tissue samples such as blood [7]. In 
our study, we observed disease-associated differences in 
genome-wide DNA methylation profiles of esophageal 
biopsies obtained from children diagnosed with EoE and 
matched non-EoE controls. Indeed, the top 25 differ-
entially methylated CpG loci were sufficient to separate 
most samples accurately according to diagnosis, high-
lighting the potential use of such signatures as diagnostic 
biomarkers in EoE. Interestingly, following initiation of 
first-line treatment for EoE, and despite reduced number 
of eosinophils in the esophageal mucosa, DNA meth-
ylation profiles in follow-up samples continued to differ 
significantly from those of healthy controls. While our 
sample size was insufficient to test for a potential corre-
lation with treatment response, the discrepancy between 
DNA methylation signatures and mucosal eosinophil 
count further highlights the major potential of this epige-
netic mark in providing additional information to further 
guide treatment. Indeed, a recent study by Jensen et  al. 
demonstrated that DNA methylation changes in esopha-
geal biopsies obtained from adults with EoE before and 
after treatment seemed to correlate with clinical signs of 
treatment response [5]. The authors also observed accel-
erated aging in EoE patient-derived esophageal tissue 
samples but not in healthy controls. Although we were 
unable to confirm these findings in our sample cohort, 
we did observe a significant association between DNA 
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methylation and age further highlighting the importance 
of considering age in future studies.
In summary, our study adds further evidence for the 
potential use of DNA methylation signatures as clinical 
biomarkers in EoE. Further studies in larger datasets are 
required to address specific value of this epigenetic sig-
nature in aiding diagnosis, predicting prognosis and/or 
monitor response to treatment.
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